Reviva Pharmaceuticals -CW23RVPHWPreferred / convertible
13F holders, Q2 2024 (June 30)4holders −1
0new positions
1sold out
$0.26avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding Reviva Pharmaceuticals -CW23 (RVPHW) in their 13F filings, down 1 from Q1 2024. 0 opened new positions and 1 sold out. The largest holders were Arena Investors LP ($21K), Walleye Capital LLC ($9K) and Walleye Trading LLC ($7K).
- Company
- Reviva Pharmaceuticals -CW23
- CUSIP
- 76152G118
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $17K |
All 13F filers, Q1 2024 → Q2 2024: 2,279 shares bought and 11,101 shares sold, net −8,822 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Arena Investors LP | — | No change | 85,000 | $21K |
| Walleye Capital LLC | — | No change | 33,718 | $9K |
| Walleye Trading LLC | — | No change | 25,727 | $7K |
| UBS Group AG | — | Add +95.7% | 4,661 | $1K |
"% of holder's portfolio" is RVPHW's weight in each manager's 13F, not the share of Reviva Pharmaceuticals -CW23 the manager owns.